Idogen develop tolerogenic vaccines which reprogram the immune system.

The company’s technology platform has the potential to develop long-acting treatment of autoimmune diseases that currently can not be cured. In addition, Idogen has the potential to change the transplantation market by reducing the need for immunosuppressive therapy after transplantation. Idogen was founded in 2008 based on an immunological discovery at Lund University.